KD Smart contains a 1:4 ratio of EPA:DHA.
Photo © iStockphoto.com/Rinelle
Omega-3 ingredients supplier KD Pharma (Bexbach, Germany) has launched KD Smart, a prenatal omega-3 oil formulated with the same ratio of omega-3 fatty acids EPA and DHA contained in mother’s milk.
Specifically, the ingredient contains a 1:4 ratio of EPA:DHA. “KD Smart is an important product for us,” said Rene Kamminga, vice president, nutrition, KD Pharma, in a press release. “DHA plays a critical role in eye and cognitive health starting right from early development and continuing on throughout life. This particular product is designed to ensure expecting or nursing mothers receive sufficient DHA for both themselves and their growing baby.”
The company cites studies showing that DHA is especially needed during gestation and says the buildup of DHA in the infant’s brain, eye retina, and throughout the body happens most rapidly from gestation through the age of two. Because the body does not produce significant levels of DHA or EPA, supplementation during the prenatal stage is crucial, it adds.
Earlier this year, Nutritional Outlook reported on a recent meta-analysis concluding that prenatal omega-3 fatty acid consumption may help prevent preterm delivery. The study was published in the European Journal of Obstetrics & Gynecology and Reproductive Biology.
Also read:
Widespread Omega-3 Usage Could Save €12.9 Billion in Annual EU Healthcare Costs, Study Suggests
Adults Should Consume 500 mg EPA and DHA Omega-3s Daily, GOED Says
High-Priority Nutrients for Kids
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.